Boris Borodulin, MD
Psychiatry · East Brunswick, NJNPI 1770646358
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $98,339 of the $116,142 with a category attached, or 84.7%. AbbVie accounts for 71.7% of it on its own, with 33 other manufacturers making up the rest. Among psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,585 payments — averaging $73.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$83K
- Otsuka America Pharmaceutical, Inc.$16K
- Idorsia Pharmaceuticals US Inc$5K
- Takeda Pharmaceuticals U.S.A., Inc.$4K
- Lundbeck LLC$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$991
- plus $5K from 28 others
What the payments were for
- Speaking & faculty fees$98,33985%
- Travel & lodging$1,3441%
- Food & beverage$16,26114%
- Education$1980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 546 | $83,264 |
| Otsuka America Pharmaceutical, Inc. | 276 | $16,293 |
| Idorsia Pharmaceuticals US Inc | 10 | $5,032 |
| Takeda Pharmaceuticals U.S.A., Inc. | 123 | $4,239 |
| Lundbeck LLC | 194 | $1,417 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 91 | $991 |
| Axsome Therapeutics, Inc. | 73 | $840 |
| Neurocrine Biosciences, Inc. | 49 | $744 |
| Teva Pharmaceuticals USA, Inc. | 24 | $552 |
| Bausch Health US, LLC | 27 | $373 |
| Vanda Pharmaceuticals Inc. | 22 | $308 |
| Alkermes, Inc. | 17 | $253 |
| Corium, LLC | 18 | $227 |
| Supernus Pharmaceuticals, Inc. | 11 | $223 |
| Jazz Pharmaceuticals Inc. | 20 | $183 |
| E.r. Squibb & Sons, L.L.C. | 12 | $181 |
| Johnson & Johnson | 9 | $140 |
| Neos Therapeutics, LP | 8 | $106 |
| Noven Therapeutics, LLC | 7 | $95 |
| Eisai Inc. | 6 | $83 |
| Acadia Pharmaceuticals Inc | 6 | $80 |
| Tris Pharma Inc | 6 | $78 |
| Almatica Pharma LLC | 5 | $69 |
| Ironshore Pharmaceuticals Inc. | 4 | $62 |
| Collegium Pharmaceutical, Inc. | 4 | $61 |
| Adlon Therapeutics L.p. | 4 | $56 |
| Merck | 4 | $51 |
| Biogen | 2 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Brainsway USA Inc | 1 | $27 |
| Tonix Medicines, Inc. | 1 | $19 |
| OWP Pharmaceuticals, Inc. | 1 | $15 |
| Sage Therapeutics, LLC | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$77,823
- REXULTI$13,674
- QUVIVIQ$4,918
- TRINTELLIX$2,640
How this compares
$116,142 in reported general payments places this provider in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 31 | $254,892 |
| VraylarCariprazine Hcl | 166 | $238,621 |
| RexultiBrexpiprazole | 85 | $143,965 |
| AustedoDeutetrabenazine | 14 | $67,556 |
| FanaptIloperidone | 14 | $44,005 |
| Risperdal ConstaRisperidone Microspheres | 29 | $31,642 |
| TrintellixVortioxetine Hydrobromide | 43 | $27,501 |
| Aripiprazole | 515 | $26,184 |
| Memantine Hcl ErMemantine Hcl | 173 | $22,307 |
| NamzaricMemantine Hcl/Donepezil Hcl | 16 | $15,020 |
| VyvanseLisdexamfetamine Dimesylate | 36 | $13,689 |
| Rivastigmine | 58 | $11,575 |
| Quetiapine Fumarate | 608 | $10,728 |
| Duloxetine Hcl | 568 | $10,304 |
| Risperidone ErRisperidone Microspheres | 21 | $8,258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $744 | $254,89231 claims |
| AbbVieVraylar, Namzaric | $83,264 | $253,640182 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $16,293 | $143,96585 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $552 | $67,55614 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $308 | $44,00514 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $4,239 | $41,18979 claims |
| Johnson & JohnsonRisperdal Consta | $140 | $31,64229 claims |
| Almatica Pharma LLCSertraline Hcl | $69 | $5,964736 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,119 psychiatry providers in New Jersey.
Other psychiatry in East Brunswick
- Marc CantillonLivingston$522K
- Robert BransfieldRed Bank$415K
- Erika ConcepcionLong Branch$354K
- Leon RosenbergCherry Hill$257K
- Lloyd AlceraMarlton$187K
- Gary SmallHackensack$170K
- Shankar SrinivasanParsippany$155K
- Matthew PiteraToms River$153K
- Anthony RostainCamden$110K
- Aijaz NanjianiParamus$95K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.